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ABBREVIATIONS 
 
AO: acridine orange 
bZIP: basic leucin zipper 
CNS: central nerveous system 
cup: curly-up phenotype characterized by dorsal curvature of the body axis 
DMSO: dimethyl sulphoxide 
dpf: days post-fertilization 
EP: ethyl pyruvate 
hpf: hours post-fertilization 
IKKβ: IκB kinase β 
IR: ionizing radiation 
LD50: lethal dose 50 
LET: linear energy transfer 
MO: morpholino 
MnSOD: manganese superoxide dismutase 
NF-κB: nuclear factor kappa B 
Nrf2: nuclear factor erythroid 2-related factor 2 
OER: oxygen enhancement ratio 
PLA2: phoshpholipase A2 
ROS: reactive oxygen species 
RT-PCR: reverse transcription polymerase chain reaction 
TMZ: temozolomide  
TNF-α: tumor necrosis factor-alpha  
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 1.  INTRODUCTION 
 
1.1.  Zebrafish 
Zebrafish embryos (Danio rerio) are emerging as a powerful vertebrate model system for 
research. Zebrafish embryos offer several important advantages compared to cell cultures or 
other conventional in vivo experimental animal models: high fecundity, high number of zebrafish 
progeny, easy upkeep at minimal cost, large sample sizes, and availability of many conventional 
cell culture techniques. The transparency of the embryo permits a visual observation of the ex 
utero development. There is high similarity between zebrafish and mammals, and the entire 
zebrafish genome is sequenced [1] [2]. The organs including the gut and the vasculature are in 
place by 48 hours post fertilization (hpf). Zebrafish embryos are permeable to small molecules, 
drugs, dyes as well as peptides, and can be transfected to express genes in a tissue-specific 
manner. Knockdown of individual mRNAs is easily achieved by morpholino antisense 
oligodeoxinucleotides.  
In addition, we have established zebrafish embryos as an in vivo vertebrate system to evaluate 
toxic effects of ionizing radiation (IR) and modifiers of IR.  
 
1.2.  Radiation-induced damage 
The mechanisms leading to the deleterious effects of ionizing radiation are multifactorial.  
IR can cause damage through energy deposition. Radiation can damage cells directly and 
indirectly. Many molecules in cells will be altered due to direct energy deposition or because of 
indirect effects as a consequence of energy transfer from one molecule to another.  With low 
LET (linear energy transfer) radiation, as  photons (gamma-or x-ray), mostly indirect effects 
occur, leading to single strand breaks. Charged particles, such as protons and heavy ions, can 
cause direct damage to cancer cell DNA through high LET and have an antitumor effect 
independent of tumor oxygen supply because these particles act mostly via direct energy transfer, 
usually causing double-strand DNA breaks. 
The interactions between low LET radiation and cells result in energy deposition in the tissues, 
generating free radicals. Free radicals derive from water in cells, which then damage the 
macromolecules. The medical use of ionizing radiation can cause a variety of side effects during 
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treatment (acute side effects) due to inflammatory cytokine release, in the months or years 
following treatment (long-term side effects) as a consequence of cell death or after re-treatment 
(cumulative side effects).  
Tissue damage associated with inflammatory changes often limits the dose of ionizing radiation 
that can be safely delivered during radiation therapy. The gastrointestinal tract is particularly 
sensitive to radiation. A well-known example of this is inflammation of the oral mucosa or the 
intestinal lining following chemo – and/or radiotherapy [3]. A hallmark of IR-associated 
inflammation is the increased liberation of pro-inflammatory cytokines including TNF-α and IL-
6, both locally and systematically [4]. In contrast to intracellular regulators of the DNA damage 
response, these and other inflammatory mediators act in a paracrine fashion affecting diverse cell 
types in the tissue microenvironment or even at a distance [5].  
 
1.3.  Radiation sensitivity of normal tissues 
Cells are intrinsically sensitive to irradiation. The nature, severity, and longevity of radiation 
effects depend on the cell type, proliferation, intracellular and microenvironmental factors as 
well as on the type of radiation, dose, and fractionation. Rapidly dividing and immature cells are 
more sensitive to ionizing radiation than differentiated cells, with the exception of lymphocytes. 
Bergonie and Tribondeau defined radiation sensitivity based on the mitotic activity. Rubin and 
Casarett classified five categories of cell populations using histological signs of cell death, as 
follows: 
 
Cell type Characteristics Examples Radiation sensitivity 
Vegetative intermitotic cells  Rapidly and regularly dividing, 
undifferentiated cells which do not 
divide between divisions 
erythroblasts, basal cells of 
epidermis, crypt cells of intestine, 
type A spermatogonia 
 
High 
Differentiating intermitotic cells  Actively dividing, more  differentiated 
cells which divide between divisions 
myelocytes, intermediate 
spermatogonia 
 
Multipotential connective tissue cells Irregularly dividing cells endothelial cells, fibroblasts  
Reverting postmitotic cells  Variably differentiated cells which do 
not normally divide but  they retain the 
capability of division 
lymphocytes, parenchymal cells 
of liver, kidney, pancreas 
 
Fixed post-mitotic cells  Highly differentiated cells which do not 
divide 
red blood cells, nerve cells, 
muscle cells, spermatozoa 
 
Low 
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Radiation sensitivity to low LET radiation also depends on the oxygen level of the tissue. The 
more oxygenated the more sensitive the tissue is. Radiation sensitivity reaches its maximum at 
an oxygen tension of 30 mmHg and does not significantly change by increasing the oxygen 
tension. Since normal tissues have an oxygen tension ranging from 40 to 120 mmHg; therefore, 
the oxygen tension does not interfere with the radiation sensitivity in healthy normal tissues.  
 
 
Dependence of radiosensitivity on oxygen tension 
 
1.4.  Radiation modifiers 
There is a great interest in developing radioprotectors to prevent normal tissue toxicity during 
chemo- and/or radiotherapy or nuclear accidents. On the other hand, the most successful way to 
treat certain cancers is through multimodality therapy. In one of our studies, we put emphasis on 
the postoperative management of patients with primary glioblastoma multiforme. Groups of 
patients treated with combinations of different therapeutic modalities were compared to each 
other and evaluated [6]. Temozolomide (TMZ) was used as a chemotherapeutic agent. The 
alkylating agent TMZ, when administered simultaneously with radiation therapy, can improve 
the effectiveness of treatment by making tumor cells more sensitive to radiation. At the same 
time, sparing healthy tissues of the central nervous system (CNS) from radiation injury and 
increasing radiation tolerance in normal tissues of the CNS play an essential role in improving 
the therapeutic index. To develop approaches to prophylaxis/protection, mitigation and treatment 
of radiation injuries, appropriate models are needed, which integrate the complex events that can 
occur in the organism exposed to radiation. While the spectrum of agents in clinical use or 
preclinical development is limited, new research findings promise improvements in survival after 
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whole-body irradiation and reductions in the risk of adverse effects of radiotherapy. The 
approaches include protective agents that act on the initial radiochemical events, mitigating 
agents that prevent or reduce progression of the radiation damage, and agents that facilitate 
recovery from radiation injuries. 
Ideally, radioprotectors can prevent normal tissues from the deleterious effects of ionizing 
radiation; whereas radiation sensitizers can make tumor cells more sensitive to radiation, 
enhancing the efficacy of radiotherapy. Generally, radioprotectors work on low linear energy 
transfer and only have a protective effect as great as the oxygen enhancement ratio (OER). 
Mostly, radioprotectors afford protection against ionizing radiation when given prophylactically.  
There are a few main groups of radioprotectors:  
- One of the groups involves those agents that can reduce the amount of oxygen by causing 
vasoconstriction and relative hypoxia, such as cyanide, epinephrine, histamine, or serotonin. 
However, these agents are not suitable for radioprotection in clinical settings.  
- The other group consists of free radical scavengers: Vitamins C and E, intracellular MnSOD, 
and compounds containing sulfhydryl (-SH) groups, such as glutathione and cysteine, which are 
well-known antioxidants. 
The above-mentioned two groups can mainly work by opposing the oxygen effect. 
- Whereas other agents can provide radioprotection by targeting molecular pathways.  
 
AIMS 
 
The aim of our study was to assess agents that can modify the radiation response. We evaluated 
whether the agents under investigation could prevent normal tissues from the deleterious effects 
of total body irradiation and whether any of these compounds could mitigate the deleterious 
effects of irradiation. 
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2.  MATERIALS and METHODS 
 
2.1.  DF-1, the free radical scavenger-type radioprotector 
DF-1 (C-Sixty, Inc., Houston, TX) is a hydrophilic antioxidant based on the hollow 
nanostructure of fullerenes. 
Fullerenes represent a family of molecules composed of 20, 40, 60, 70, or 84 carbon atoms. 
Fullerenes have the potential to scavenge reactive oxygen species (ROS), including hydrogen 
peroxide, hydroxyl radicals, hydroperoxy radicals, and superoxide, but their basic structures are 
not water-soluble without modification. C60 fullerene is the most frequently used member of this 
family [7]. DF-1 is a C60 fullerene derivative (dendrofullerene) that contains 18 carboxylic 
groups to enhance water solubility [8]. DF-1 has been known to exert powerful antioxidant 
effects in vitro [9]. 
 
2.2.  Direct inhibitors of NF-κB and proteasome inhibitors 
The nuclear factor κB (NF-κB) family of transcription factors represents a diverse and shared 
signaling mechanism activated during cell stress responses [10]. Deregulated NF-κB signaling 
has been implicated in the malignant phenotype and treatment resistance of select tumor forms 
[11-15]. The canonical pathway to NF-κB activation leads to IκB kinase β (IKKβ)-dependent 
phosphorylation and subsequent proteasomal degradation of the NF-κB inhibitor IκB, increased 
nuclear presence of NF-κB dimers, and enhanced NF-κB-dependent transcriptional activity [10]. 
Whole-body radioprotection through anti-inflammatory agents has been shown in animal 
models. Specifically, certain triterpenoids (CDDO and derivatives thereof) have been shown to 
selectively protect normal mouse tissues against the deleterious effects of ionizing radiation [16]. 
Furthermore, EP, a derivative of the end product of glycolysis, similarly protects normal cells 
against the deleterious effects of radiation both in vitro and in mice [17].  
Both CDDO-TFEA and EP inhibits activation of NF-κB. EP inhibits NF-κB signaling through 
direct molecular interaction with a reactive cysteine of the p65 subunit of NF-κB [18] whereas 
CDDO-TFEA binds to a reactive cysteine (Cys 179) of IKKα, thus inhibiting its kinase activity 
12 
 
  
[19]. However, these compounds also target other signaling molecules and pathways of potential 
relevance to the radiation response, including signal transducers and activators of transcription 3 
and Jaks [20, 21]. 
Additionally, four pharmacologic IKK inhibitors with different modes of action were also tested.  
In addition to these agents, proteasome inhibitors were also evaluated. They have been shown to 
inhibit NF-κB-dependent transcription, and one of these (PS-341; Bortezomib; VELCADE) has 
been approved for clinical use in patients with multiple myeloma [22, 23].  
 
2.3.  Embryo harvesting and maintenance 
Wild-type zebrafish were mated in embryo collection tanks. Viable embryos were washed and 
plated at the one- to two-cell developmental stage and kept under normoxic conditions at 28.5 
˚C. Embryo medium was changed at every 24 hours. In select experiments, embryos (24 hpf) 
were dechorionated by placement in embryo medium supplemented with 50 µg/mL pronase 
(Sigma) for approximately 10 min at room temperature, then gently agitated with a plastic 
pipette until the embryos were liberated from the disrupted chorions. After dechorionation, the 
embryos were rinsed thoroughly with embryo medium, and placed in fresh embryo medium. 
 
2.4.  Radiation exposure and drug treatments 
 
2.4.1.  DF-1 
DF-1 was dissolved in embryo medium containing no more than 0.4% dimethyl sulphoxide 
(DMSO). Embryo medium containing 0.4% DMSO was used as a vehicle control in the DF-1 
experiments since DMSO is known to possess radioprotective effects. Amifostine was used as a 
positive control in select experiments and was used at 4 mmol/L, which is the efficient 
concentration previously described for radioprotection [24]. Unless stated otherwise, embryos 
were exposed to a single dose of ionizing radiation ranging dose from 0 to 40 Gy at 24 hpf using 
either a 
137
Cs radiation source or an X-ray machine. DF-1 toxicity analysis was conducted using 
a dilution series of 0, 10, 100, and 1000 µmol/L DF-1 in the absence of radiation. To determine 
modulation of radiation induced toxicity, DF-1 was added at 100 µmol/L to embryos for 3 hours 
and 30, 15, or 5 minutes before radiation exposure and 5, 15, or 30 minutes after radiation 
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exposure. After irradiation, zebrafish embryos were kept at 28.5 C for up to 7 days post 
fertilization to monitor effects of treatments on survival, morphology, and organ-specific 
toxicity.  
 
2.4.2.  Manganese superoxide dismutase mimetics 
We used zebrafish embryos to explore the putative radioprotective effects of  two manganese 
superoxide dismutase (MnSOD) mimetics;  M40403 (ActivBiotics, formerly Metaphore, 
Lexington, MA) and  MnTE-2-PyP5+ (Duke University). M40403 is a stable, non-peptidyl, 
synthetic manganese superoxide dismutase mimetic (MnSOD) with a low molecular weight, 
which eliminates superoxide anions (
.
O2
−
) without interfering with other radicals known to be 
involved in inflammatory responses [25]. MnTe-2-PyP5+ is a synthetic SOD mimetic, which 
was synthesized as described by Batinic-Haberle et al. [26]. 
Radioprotection was assessed by determining drug effects on IR-associated mortality. To 
evaluate in vivo toxicity of these agents, zebrafish embryos at 24 hours post fertilization (hpf) 
were exposed to log-fold dilution series until 144 hpf.  Based on the toxicity profiles, zebrafish 
embryos (24 hpf) were exposed to IR (20 Gy) with either MnTE-2-PyP5+ (2.5 µM) or M40403 
(100 µM) or Amifostine (4 mM) administered 3 h prior to ionizing radiation.  Embryos were 
evaluated at 24-h intervals until 168 hpf for viability and radiation-induced gross morphological 
alterations. 
 
2.4.3.  Direct inhibitors of NF-κB and proteasome inhibitors 
Pharmacologic agents (EP; CDDO-TFEA; IKK inhibitors: IKK Inhibitor 2 (Wedelolactone), 
IKK Inhibitor 3 (BMS-345541), IKK-2 Inhibitor 4 and IKK-2 Inhibitor 5 (IMD-0354); MG132; 
PS-341, and Lactacystin) were dissolved in EM containing <0.1% DMSO. EM was used as a 
vehicle control in all experiments. Unless stated otherwise embryos were exposed to ionizing 
radiation ranging in dose from 0-20 Gy at 24 hpf using an X-ray machine (Gulmay Medical, 
Bethel, CT) or a 
137
Cs radiation source. 
Toxicity analyses for EP (<10 mM), CDDO-TFEA (<10 µM), PS-341 (<10 µM), MG132 (<50 
µM) or Lactacystin (<10 µM) were conducted by monitoring survival and development of 
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zebrafish embryos for 7 days in the absence of radiation. To determine modulation of radiation-
induced toxicity, EP (1 mM) or CDDO-TFEA (1 µM) was added to embryos either 1h before or 
up to 3 h after radiation exposure at 24 hpf.  The proteasome inhibitors were added to zebrafish 
embryos 1 h prior to IR.  After irradiation, zebrafish embryos were maintained at 28.5 ˚C for up 
to 7 days post fertilization (dpf) to monitor effects of treatments on survival, morphology and 
organ-specific toxicity.   
 
2.5.  Analysis of treatment effects on zebrafish morphology and survival 
Dechorionated embryos at 72 hpf were anesthetized with 1:100 dilution of 4 mg/mL tricaine 
methanesulfonate and immobilized by placing them on 3% methylcellulose on a glass depression 
slide. Morphology was assessed visually using a light transmission microscope at 40 to 100X 
magnification, and representative images were recorded. Similarly, survival of embryos was 
assessed visually at 24-hour intervals up to 168 hpf by light microscopy. The criterion for 
viability was the presence of cardiac contractility.  
 
2.6.  Renal function assay  
Clearance of tetramethylrhodamine-labeled, 10-kDa dextran from the cardiac area was 
determined. Briefly, zebrafish embryos at 24 hpf were exposed to ionizing radiation and 
maintained in embryo medium. At 72 hpf, zebrafish embryos were anesthetized using a 1:100 
dilution of 4 mg/mL tricaine methanesulfonate and dorsally positioned on 3% methylcellulose 
gel. Tetramethylrhodamine-labeled, 10-kDa dextran (Molecular Probes, Eugene, OR) was 
injected into the cardiac venous sinus; embryos were kept at 28.5 ºC and imaged 1 and 24 hours 
following microinjection. The average fluorescence emission at 590 nm following excitation at 
570 nm was detected at the center of the cardiac area, and the relative intensity was measured 
using a Leica microscope. Images were transformed into grayscale and evaluated with NIH 
ImageJ software as described by Hentschel et al. [27]. 
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2.7.  Histopathology and evaluation of embryos treated with DF-1 
Zebrafish embryos were evaluated histopathologically for morphologic alterations of ionizing 
radiation exposure and the potential radioprotective effects of DF-1. Briefly, embryos at 4 dpf 
were exposed to 0, 20, or 20 Gy plus DF-1 (100 µmol/L) given 3 hours before radiation 
exposure. Following sacrifice using a 1:100 dilution of 4 mg/mL tricaine methanesulfonate 
(Sigma), embryos were initially fixed and preserved in Davidson’s solution for 24 hours and then 
rinsed and placed in 10% neutral buffered formalin for a minimum of 4 days. All specimens 
were processed in graded alcohol (70-100%), cleared twice at 10 minutes each in Clear-Rite 3, 
and infiltrated with paraffin (Paraplast, McCormick Scientific, St. Louis, MO). Sections were 
embedded in paraffin, and transverse whole-body sections (4-6 μm thickness; 100-120 sections 
per fish) were made (Leica RM 2135 rotary microtome, Leica, Inc.) serially from the rostral 
aspect of the head to the mid-trunk region of each fish. All sections were stained with modified 
Mayer’s hematoxylin 2 and eosin-Y, mounted on glass slides, and coverslipped. Sections were 
examined by light microscope (Olympus BX51, Olympus) at 4 to 40X magnification, and 
representative images were recorded using a SPOT camera and SPOT Advanced software (SPOT 
Diagnostic Instruments). 
 
2.8.  Detection of ROS 
Production of ROS was measured in dechorionated whole zebrafish embryos at 24 hpf in 96-well 
plates. Embryos (one per well) were treated with either vehicle (<0.4% DMSO in embryo 
medium) or the agent to be tested (namely DF-1 at 100 µmol/L or EP at 1 mmol/L or CDDO-
TFEA at 1 µmol/L) in the presence of 5-(and-6)-chloromethyl 2,7-dihydrodichlorofluorescein 
diacetate (CM-H2DCFA; Molecular Probes) followed by radiation exposure at 24 hpf. Zebrafish 
embryos were incubated in EM containing one of the above-mentioned agents before ionizing 
radiation at 24 hours; the fluorescent dye CM-H2DCFA (500 ng/mL) was added 1 hour before 
radiation exposure. The average fluorescence emission at 530 nm following excitation at 490 nm 
was detected immediately and 2 hours after ionizing radiation exposure using a microplate 
fluorescent reader. To account for radiation-induced ROS in the embryo medium results were 
corrected by subtraction of values obtained in wells not containing fish in the presence and 
absence of pharmacologic agents. 
 
16 
 
  
2.9.  Apoptosis assay   
Quantitative apoptosis measurements were performed by staining with the vital dye acridine 
orange (AO) that permeates dying cells to bind to chromatin.  Zebrafish embryos were incubated 
for 1 h in EM containing one of the radiation modifiers and irradiated with 20 Gy at 24 hpf. Six 
hours later, zebrafish embryos were manually dechorionated and stained for 15 minutes using 5 
µg/mL of Acridine Orange dye (Sigma) and rinsed five times with EM [28]. Zebrafish embryos 
were then imaged with QIMAGING camera and iVision software, and the images were then 
analyzed using ImageJ software. 
 
2.10.  Morphologic analysis of the gastrointestinal system 
The functional and morphologic integrity of the developing gastrointestinal system was assessed 
in zebrafish embryos using PED6, a fluorescent reporter of phospholipase A2 (PLA2) activity. 
To evaluate intestinal lipid processing, PED6 (Molecular Probes, Eugene, OR) was added to 
zebrafish at day 5 and images were taken at day 6 with the average fluorescence emission at 540 
nm following excitation at 505 nm. PED6 is a fluorogenic substrate for PLA2, which contains a 
BODIPY FL dye–labeled acyl chain and a dinitrophenyl quencher group [29]. The cleavage of 
the dye-labeled acyl chain by PLA2 within cells lining the intestine unquenches the dye and leads 
to detectable fluorescence in the lumen of the developing gastrointestinal tract.  PED6 was added 
to zebrafish embryos at 5 dpf followed by imaging the fish at 6 dpf with the average fluorescence 
emission at 540 nm excitation at 505 nm. Images were taken at 6 dpf using a Leica microscope 
and analyzed using the ImageJ software. 
 
2.11.  Histopathology and evaluation of tissue morphology in zebrafish embryos treated 
with either EP or CDDO-TFEA 
Zebrafish embryos were evaluated histopathologically for morphologic alterations induced by 
radiation exposure and potential radioprotective effects of EP and CDDO-TFEA with special 
emphasis on the gastrointestinal morphology. Briefly, embryos at 24 hpf were exposed to 0 or 12 
Gy in the presence or absence of either CDDO-TFEA or EP administered 1 h prior to ionizing 
radiation. Embryos were sacrificed, fixed by immersion in 4 % paraformaldehyde for 24 h, and 
then rinsed and placed in 10x PBS for another 24 h. Sections were embedded in paraffin, and 
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coronal, transverse, and sagittal whole-body sections (4 µm thickness) were generated. All 
sections were stained with H&E, mounted on glass slides, and examined by light microscope; 
representative images were taken using a QIMAGING camera and iVision software.  
 
2.12.  NF-κB reporter assay   
NF-κB reporter assay was done as described by Ren et al. [30] with minor modifications. HeLa 
cells were seeded at 7.5 x 10
4
/ml in DMEM medium supplemented with 10% fetal bovine serum. 
The cells were co-transfected with the pSEAP2- NF-κB vector (BD BioSciences) encoding a 
secreted form of human placental alkaline phosphatase driven by a NF-κB-responsive promoter 
and a β-galactosidase expression vector for control purposes. Forty-eight hours post transfection, 
different NF-κB inhibitors (Velcade, 0.5 μ M; MG-132, 5 μM; EP, 1mM; CDDO-TFEA, 1 μM) 
were added to the cells in serum-free media for 24 hours. NF-κB-dependent transcription in the 
absence and presence of recombinant TNF-α (10 ng/ml; R&D Systems) was determined 72 hours 
post transfection using the Great EscAPe SEAP Reporter System 3, which is based on detection 
of secreted alkaline phosphatase in cell supernatants normalized to β-galactosidase activity using 
the luminescent β -gal detection kit (BD Biosciences).  
 
2.13.  Reverse transcription polymerase chain reaction (RT-PCR) analysis   
Zebrafish total RNA was isolated form 100 embryos per experimental condition at 30 hpf (6 h 
post radiation) using the RNeasy mini kit (QIAGEN Sciences, Maryland, USA) and stored at -80 
°C. For reverse transcription, total RNA was annealed with Oligo(dT) primer at 70°C for 5 min 
and then incubated at 42°C for 1 h. Reverse transcription reaction products were boiled for 2 min 
followed by incubation on ice for 2 min before use. Primer sequences used for amplification of 
bax, mdm2, p21/waf-1 and β-actin zebrafish sequences are provided in Supplementary Table S1 
of paper II in the appendix. PCR reaction conditions were 94 ˚C, 60 ˚C, 72 ˚C for 30 sec., 30 
sec., 1 min., respectively and 35 cycles with 7 min. extension time after the last cycle.  Thermo 
Fisher Scientific Taq-polymerase was used in 50 µL PCR reaction mix containing 1 µL RT 
reaction. PCR reactions were analyzed by 1.5% agarose gel electrophoresis. 
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2.14.  Use of morpholinos 
Morpholino antisense oligonucleotides (MO) have commonly been used to achieve sequence-
specific gene knockdown.  Zebrafish embryos were injected at 1-2 cell stage with an 
approximately 3-5 ng MO per embryo to study signaling in developing zebrafish embryos. 
Control embryos were mock-injected with control MO. 
 
2.15.  Statistical analysis   
All experiments were performed at least three times with at least 75 embryos total per 
experimental group.  To determine statistically significant differences between groups, χ2-tests 
were performed.   
 
3.  RESULTS 
3.1.  DF-1 
3.1.1.  Toxicity profile of DF-1 
DF-1 toxicity analysis was conducted using a dilution series of 0, 10, 100, and 1,000 µmol/L of 
DF-1 in the absence of radiation. No adverse affects were noted on either survival or gross 
morphology throughout the concentration range tested, up to 1 mmol/L (Fig. 1 A).  
3.1.2.  Effect of DF-1 on survival of zebrafish embryos exposed to ionizing radiation 
We focused on the radioprotective effects of DF-1 as determined by viability assessment of 
irradiated zebrafish embryos pretreated with the fullerene. Embryos were exposed at 24 hpf to 
either 20 or 40 Gy based on our previous observation that, at this stage of development, 20 Gy 
represents the LD50. In addition, organogenesis has commenced by 24 hpf; thus, this time point 
is a preferred developmental stage to assess radiation-induced effects on most major organs. DF-
1 given before radiation prolonged survival significantly in zebrafish embryos when exposed to 
either 20 or 40 Gy. This effect was maximal at a concentration of 100 µmol/L (Fig. 1 B). At 40 
Gy, protection was only partial, but all embryos eventually died within the observation period of 
up to 6 dpf (Fig. 1 D). DF-1 (100 µmol/L) provided a level of radioprotection, which was similar 
to that provided by 4 mmol/L amifostine (Fig. 1 C and D).  
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Figure 1   
A, Toxicity profile of DF-1 as assessed by survival of 
zebrafish embryos. The time-dependent survival of 
embryos exposed to DF-1 at 24 hpf at concentrations 
ranging from 10 to 1,000 μmol/L.  
 
 
 
 
B, Dose-dependent effects on survival (at day 6 of 
development) of zebrafish embryos exposed to 20 Gy 
ionizing radiation at 24 hpf in the presence of 
increasing concentrations of DF-1. DF-1 was given 3 
hours before irradiation.  
 
 
C and D, Comparison of radioprotection afforded by 
DF-1 and amifostine administration to zebrafish 
embryos exposed to 20 or 40 Gy ionizing radiation at 
24 hpf. Drugs were given 3 hours before irradiation, 
and overall survival was scored for up to 6 dpf. •, 
vehicle (DMSO, 0.4 %) control; ○, DF-1 (100 
μmol/L); ▾, amifostine (4 mmol/L). 
Time course experiments showed that maximal rescue of radiation-associated lethality and gross 
morphologic defects was achieved when DF-1 was given 3 hours, compared with 30, 15, or 5 
minutes, before  ionizing radiation treatment. We also assessed whether DF-1 could be used to 
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mitigate radiation effects on survival when given after radiation exposure. DF-1 did not confer a 
survival advantage to zebrafish embryos when given 30 minutes after 20 Gy ionizing radiation 
exposure. However, DF-1 significantly enhanced survival when given concurrently or up to 15 
minutes after irradiation (Fig. 2).  
 
 
Figure 2 Mitigating effects of DF-1 on radiation-induced lethality in zebrafish embryos. DF-1 (100 
μmol/L) was given 5, 15, or 30 minutes after irradiation (20 Gy), and survival was assessed for 5 days. When 
given 30 minutes after radiation, DF-1 did not affect embryonic survival after exposure. Vehicle control (•); 
100 μmol/L DF-1, 5 minutes (○), 15 minutes (▾), and 30 minutes (▵) after irradiation. 
 
3.1.3.  DF-1 alleviates radiation-induced defects in midline development 
To obtain a more detailed view of DF-1-mediated radioprotection, we evaluated the effects of 
this drug on organ-specific, radiation-induced damage. We assessed the effects of DF-1 on a 
commonly observed and easily scored phenotype apparent within 1 to 2 days following ionizing 
radiation exposure of zebrafish. This phenotype consists of dorsal curvature of the body axis 
previously described as “curly-up” or “cup” and ascribed to defects in midline development of 
zebrafish embryos [31]. Although the mechanism leading to “cup”  is presently unknown¸ the 
ease with which this phenotype can be observed makes it an attractive parameter to score 
radiation toxicity in zebrafish embryos (Fig. 3).  We observed that throughout the dose range 
tested, DF-1 markedly reduced the incidence of “cup”.  Depending on the IR dose, it either 
reduced the severity or abolished the dorsal curvature altogether.  
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Figure 3 DF-1 protects against radiation-induced defects in midline development.  Radiation-induced 
morphological changes in body axis were assessed at 3 dpf.  A, Representative pictures of IR-induced dorsal 
curvature (``cup`` phenotype) in zebrafish and attenuation of this effect by DF-1 (100 µM) administered 3 h 
prior to IR (24 hpf). B, The bar graph shows the quantitative representation of the results after 20 or 40 Gy 
IR as indicated.  Statistically significant differences (p= 0.0077) between control and experimental groups are 
indicated by asterices. 
 
 
3.1.4.  DF-1 attenuates radiation-induced renal function defects 
Radiation exposure of embryos produced extensive edema in the developing fish, and this effect 
was reversed by DF-1 treatment. We hypothesized that this phenotype was due to impaired renal 
function after radiation, an effect well documented in mammals, including humans [32]. To 
address this issue, we used an excretory function assay, which measures clearance of a 
fluorescent dextran within 24 hours after injection into the cardiac venous sinus [27]. Compared 
with non-irradiated controls, exposure to 20 Gy ionizing radiation markedly reduced clearance of 
this agent. By contrast, pretreatment of embryos with 100 µmol/L DF-1 restored clearance to 
levels indistinguishable from those observed in non-irradiated fish embryos (Fig. 4).  
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Figure 4 DF-1 attenuates radiation-associated reduction in dextran clearance. A, Representative 
photomicrographs illustrating clearance of tetramethylrhodamine-labeled 10 kDa dextran after 24 h after 
cardiac injection in irradiated and control fish embryos.  Radiation (20 Gy) led to delayed clearance 
measured at 24 h.  The bar graph shows the quantitative representation of results obtained by using the NIH 
Image J software.  Reduction of dextran clearance by radiation exposure (20 Gy) was significant (p=0.029) 
and abrogated by DF-1 (100 μM) administered 3 hours prior to IR. B, IR was associated with renal 
glomerular changes that are not mitigated by DF-1. C, Pronephric glomerulus from embryo exposed to 20 Gy 
ionizing radiation at 4 dpf is relatively smaller than control and the glomerular tuft is less cellular. D, 
treatment with DF-1 does not lessen IR-associated changes in pronephric glomerulus in embryo exposed to 20 
Gy at 24 hpf. 
 
Thus, DF-1 appears to restore compromised excretory function in irradiated zebrafish embryos. 
To determine whether this effect was due to protection of renal tissue against radiation effects, 
we assessed the effects of different treatments on renal tissue architecture. Compared with 
unirradiated control fish, embryos exposed to 20 Gy ionizing radiation exhibited minimal to 
moderate apoptotic-type individual cell death involving a variety of tissues; however, in the 
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kidney, 20 Gy ionizing radiation exposure was associated with only a subtle but consistent 
decrease in the size and overall cellularity of pronephric glomeruli compared with controls (Fig. 
4B and C). This particular morphologic effect did not appear to be mitigated by DF-1 treatment 
(Fig. 4 D). We, thus, tested whether the profound edema in zebrafish embryos following ionizing 
radiation exposure was secondary to reduced cardiac function [33]. Time-lapse microscopy of 
cardiac contractility in control and irradiated fish embryos revealed only marginal effects of 20 
Gy ionizing radiation on heart rate and blood flow. These experiments show that radiation 
reduces clearance of dextran in zebrafish embryos, although it is presently unclear which cells or 
tissues are responsible for this effect. 
 
3.1.5.  Reduction of ROS in irradiated zebrafish embryos treated with DF-1  
C-60 fullerenes are known to have antioxidant effects in vitro [9]. To investigate whether DF-1 
exhibits similar effects in vivo, levels of ROS were determined in developing zebrafish embryos 
after ionizing radiation. Measurement of ROS in zebrafish revealed that free radicals following 
radiation exposure (20 Gy) were significantly diminished by DF-1 pretreatment (100 µmol/L) 
and indistinguishable from nonirradiated controls (Fig. 5). This result reveals ROS scavenging 
activity of DF-1 in vivo and suggests a putative mechanism for the observed radioprotective 
action of this fullerene in zebrafish. Note that similar studies cannot be done with amifostine due 
to molecular interactions between amifostine and the fluorescent dye, which lead to false-
positive values in the assay used. 
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Figure 5 DF-1 decreases levels of ROS in irradiated fish embryos. Embryos were exposed to ionizing 
radiation at 24 hpf in the absence or presence of DF-1 (100 µmol/L) given 3 hours before radiation.  
 
 
 
3.2.  MnSOD mimetics 
M40403 and MnTE-2-PyP5+ had no apparent adverse effect on normal zebrafish development or 
viability even at ten times the effective dose.  IR caused time- and dose-dependent perturbations 
of normal morphology and reduced survival of the exposed embryos.  Administration of M40403 
(100 μM) or MnTE-2-PyP5+ (2.5 μM) markedly attenuated radiation-induced time- and 
radiation dose-dependent morphological alterations and increased overall survival (86.7%±5.8, 
88.9%±7.7, respectively) relative to untreated but irradiated controls (55.6%±10.2).  The positive 
control Amifostine treated embryos had an 86.5%±8.3 survival. 
 
3.3.  Direct inhibitors of NF-κB and proteasome inhibitors 
 
3.3.1.  Proteasome inhibitors radiosensitize zebrafish embryos 
The proteasome inhibitor PS-341 (Bortezomib/VELCADE) with well-characterized inhibitory 
effects on NF-κB [23] has been approved for clinical use. PS-341 is a small, cell-permeable 
molecule inhibiting proteasome activity in a reversible manner. In addition to reducing the 
activation state of NF-κB by inhibiting the proteasomal degradation of IκB, PS-341 affects 
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several other molecular pathways and targets, leading to high expression levels of several 
proapoptotic proteins in certain experimental conditions [34]. In vitro, PS-341 has been found to 
enhance anti-tumor cell effects of certain chemotherapeutic agents [11, 35], ionizing radiation 
[36] and tumor cell targeting antibodies [37]. Yet, little is known about the combined effects of 
PS-341 and IR on normal cells and tissues of vertebrate organisms. To address this issue, PS-341 
was used in zebrafish embryos exposed to high doses of ionizing radiation [24, 38]. First, a 
toxicity analysis was carried out with PS-341 alone (dose range, 0–10 μmol/L). No toxicity was 
noted in the aforementioned concentration range during the first 7 days after fertilization (Fig. 6).  
 
    A         B                  C 
 
Figure 6 Toxicity analyses for PS-341 (< 10 µM), MG132 (< 50 µM) and Lactacystin (< 10 µM) . Each 
of the compounds was added to EM at 24 hpf for 6 days and survival was scored at 7dpf. Asterices indicate 
the doses used in our experiments. 
 
 
In contrast, PS-341 (1 μmol/L) markedly sensitized zebrafish embryos when administered 1 hour 
prior to radiation (Fig. 7).  
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Figure 7 Effects of the proteasome inhibitor PS-341 on the radiation sensitivity of zebrafish embryos. 
Embryos were irradiated at 24 hpf and survival was scored every day up to 7 dpf.  
 
In HeLa cells, at the same concentration (1 µmol/L) PS-341 abrogated the TNF-α-induced NF-
κB activity, whereas it did not significantly affect the basal activity (Fig. 8). 
 
 
 
 
Figure 8 Targets and effects of pharmacologic agents on NF-κB activity in vitro.  A, Effects of the 
proteasome inhibitors PS-341 and MG132 as well as EP and CDDO-TFEA on baseline NF-κB activity in 
HeLa cells.  B, Effects of compounds on TNF-α-induced NF-κB activity in HeLa cells.   
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To ascertain whether radiation sensitization by PS-341 could be reproduced using other 
inhibitors of the proteasome, we next tested the effects of MG132, a non-boronated small 
molecule inhibitor of the 26S proteasome [39], on zebrafish survival in the presence and absence 
of ionizing radiation. Similar to PS-341, MG132 was nontoxic when applied as a single agent to 
zebrafish embryos (dose range, 0–50 μmol/L), yet efficiently inhibited TNF-α–induced but not 
the baseline NF-κB activity in HeLa cells when used at 5 μmol/L (Fig. 8). At this concentration, 
however, MG132 marginally sensitized zebrafish embryos to the lethal effects of 20 Gy ionizing 
radiation albeit to a lesser degree than PS-341 (Fig. 9). An irreversible proteasome inhibitor 
(lactacystin) at a nontoxic concentration (5 μmol/L) also slightly  radiosensitized zebrafish 
embryos in a manner similar to MG132 (Fig. 10). 
 
 
 
 
Figure 9 Effects of the proteasome inhibitor MG-132 on the radiation sensitivity of zebrafish 
embryos.  Embryos were irradiated at 24 hpf. 
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Figure 10 Effects of the proteasome inhibitor lactacystin on the radiation sensitivity of zebrafish 
embryos.  Embryos were irradiated at 24 hpf. 
 
These results show that several proteasome inhibitors do not protect normal cells and tissues in 
the developing zebrafish embryos against the deleterious effects of IR. Since p53 is a main target 
of proteasome degradation and enhances IR-associated tissue damage in mice  [40-42] and 
zebrafish [43, 44] we asked whether the deleterious effects of proteasome inhibitors could be 
linked to p53 stabilization and subsequent induction of target genes. 
Consistent with our previous observations, ablating p53 expression by antisense morpholino 
oligodeoxynucleotide [45] or p53 function by PTF-α (1 µmol/L) administered at 24 hpf [44] 
markedly improved zebrafish survival following IR either alone or in combination with PS-341. 
However, reverse transcription-PCR analysis did not reveal increased steady-state mRNA levels 
of the p53 targets p21/WAF1, bax, or the zebrafish ortholog of mdm2 in PS-341-treated embryos 
whereas ionizing radiation led, as expected, to elevated transcript levels for these genes (Fig. 11). 
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Figure 11 Effects of IR and PS-341 on steady-state transcript levels of the p53 target genes p21/Waf1, 
mdm2 and bax as determined by semiquantitative PCR standardized to -actin.  The effects of EP and 
CDDO-TFEA on target gene expression are shown for comparison. 
 
 
Thus, the molecular target(s) responsible for the radiation sensitizing effects by PS-341 and their 
relationship to the p53 response remain to be identified. 
 
3.3.2.  Radiation protection of zebrafish embryos by the NF-κBp65 inhibitor ethyl pyruvate 
In consideration of the fact that proteasome inhibitors affect multiple intracellular pathways in 
addition to NF-κB and to pinpoint the functional contribution of NF-κB to the radiation response 
of zebrafish embryos, we tested the effects of a series of pharmacologic inhibitors of NF-κB 
activity with different mechanisms of action on the radiation response of zebrafish embryos. 
Reducing NF-κB activity by expression of upstream regulator IκB has been shown to cause 
several embryonic malformations in zebrafish embryos [46, 47] and, therefore, was not further 
considered. In addition, knock-down of the NF-κB p65 subunit by antisense morpholinos 
similarly caused severe morphologic defects, the ``no tail phenotype``, during the first 3 days of 
development (Fig. 12), consistent with previously published findings [47] and was not 
informative in the context of assaying the radiation response.  
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A            B 
  
 
Figure 12 Lethal effect of morpholino-mediated NF-κB knockdown on zebrafish embryos.  A, 
Morphology of NF-κB-MO-treated embryos. B, Time-dependent survival of control, control-MO (random 
control morpholino, Gene Tools) and NF-κB-MO-treated embryos. 
 
Instead, we used pharmacologic inhibitors that disrupt the canonical pathway to NF-κB 
activation and could be used at concentrations that do not interfere with embryonal development. 
First, we tested EP, a ROS scavenger and inhibitor of NF-κBp65 [48]. EP inhibits the DNA 
binding activity of the NF-κBp65 subunit by binding to a reactive cysteine in the DNA binding 
site (Cys 38) of NF- κBp65 [18], which is shared between humans and zebrafish (as shown 
below).  
 
 
EP has been shown to mitigate deleterious effects of whole-body irradiation in mice [17]. We 
observed that EP similarly not only protected against but also mitigated lethality associated with 
total body irradiation of zebrafish embryos (Fig. 13).  
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Figure 13 Protection against lethal effects of radiation (20 Gy) by direct NF-κB inhibitors (top panels). 
Survival benefit of zebrafish embryos treated with either EP (1 mmol/L) or CDDO-TFEA (1 µmol/L) 2 hours 
post radiation at 24 hpf (bottom panel). 
 
EP was administered at various time points ranging from 1 hour prior to radiation exposure to 3 
hours post-irradiation. The ROS scavengers amifostine and DF-1 were used as positive controls 
in these experiments as we observed marked protection of embryos by these two compounds in 
earlier work [24, 49]. Whereas amifostine and DF-1 afforded protection against the deleterious 
effects of ionizing radiation when administered prior to or concurrent with radiation, neither 
compound could mitigate the lethal effects of radiation when given beyond 15 minutes after 
ionizing radiation (Fig 2) [49]. In marked contrast, EP administered up to 2 hours after radiation 
significantly reduced ionizing radiation–associated lethality (Fig 13). 
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3.3.3.  The IKK inhibitor CDDO-TFEA mitigates radiation effects in zebrafish embryos 
To further address the relevance of NF-κB activation in modulating radiation sensitivity of 
zebrafish embryos, we used CDDO-TFEA that inhibits NF-κB signaling by interacting with 
Cys179 of IKKβ, inhibiting its activity and preventing phosphorylation and proteasomal 
degradation of IκB [50] and, thus, through a molecular mechanism distinct from EP. The amino 
acid sequence around this reactive Cys179 is also highly conserved in zebrafish (see below). 
 
 
CDDO-TFEA not only protected against but also mitigated overall lethal effects of radiation in 
zebrafish embryos in a manner similar to EP (Fig. 13).  
 
We next determined whether mitigation of radiation effects co-segregated with the capacity of 
the compounds under investigation to act as ROS scavengers. This was based on the findings 
that, in addition to directly binding to IKKβ, CDDO has been reported to induce expression of 
enzymes catalyzing antioxidant reactions  in peripheral blood mononuclear cells due to increased 
nuclear accumulation of Nrf2, an oxidant-responsive bZIP transcription factor [51, 52]. Whereas 
EP was an effective ROS scavenger in irradiated zebrafish embryos, CDDO-TFEA – at least at 
the concentration tested - did not reduce ROS levels measured 2 hours after radiation (Fig. 14). 
 
33 
 
  
 
Figure 14 EP but not CDDO-TFEA is an effective ROS scavenger in irradiated zebrafish embryos.  
Zebrafish embryos were exposed to IR (20 Gy) at 24 hpf and ROS levels determined at 26 hpf, i.e., 2 h after 
IR as described in Materials and Methods.  
 
Thus, at least the effect of CDDO-TFEA at 1 µM on radiation mitigation cannot be attributed to 
ROS scavenging, whereas in the case of EP, ROS scavenging and NF-κB inhibition may be 
jointly responsible for the beneficial effects of EP in the mitigation setting. The ROS scavengers 
with no known effect on NF-κB signal transduction (amifostine and DF-1) do not mitigate 
radiation effects if administered beyond 15 minutes after ionizing radiation. To further assess 
whether IKK inhibition can afford radioprotection, the following small molecule IKK inhibitors 
were tested: Wedelolactone (IKK inhibitor 2), BMS-345541 (IKK inhibitor 3) and IKK-2 
inhibitors 4 and 5. All four agents protected zebrafish embryos against the deleterious effects of 
radiation in a manner similar to CDDO-TFEA and EP (Fig. 15).  
34 
 
  
 
Figure 15 Radiation protection of zebrafish embryos exposed to 20 Gy and treated for 1 h prior to 
irradiation with different IKK inhibitors. 
 
Moreover, these IKK inhibitors are not known to have antioxidant properties and primarily 
inhibit IκBα phosphorylation by IKKβ. These results suggest that prolonged and excessive 
activation of the canonical NF-κB pathway is a major contributor to radiation toxicity in the 
developing vertebrate organism and that inhibiting this pathway may protect the organism 
against the deleterious effects of radiation. 
 
3.3.4.  Organ-specific radiation protection by CDDO-TFEA and EP  
Having established that EP and CDDO-TFEA provide whole-body protection against lethal 
doses of radiation and in consideration of the fact that these compounds are in preclinical 
development, we next determined organ-specific radiation protective effects of these two NF-κB 
inhibitors. As expected, consistent with earlier reports, unirradiated controls showed minimal AO 
positivity, in contrast, embryos exposed to 20 Gy displayed distinct AO positivity in the central 
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nervous system and along the body axis of irradiated embryos [43]. Both NF-κB inhibitors 
markedly reduced radiation-induced acridine orange staining (Fig. 16).  
 
 
Figure 16 Reduction of organism-wide apoptosis by EP and CDDO-TFEA treatment pre- and post-
radiation. Acridine orange (AO) staining of whole embryos was performed 6 hours post radiation at 30 hpf. 
A, Representative examples of control and irradiated fish revealing strong AO staining in the central nervous 
system and along the body axis induced by radiation (20 Gy). Regions selected for quantitative evaluation are 
boxed. B, Reduced AO staining in CDDO-TFEA and EP-treated embryos exposed to IR. C, PS-341 or MG132 
treatment does not significantly affect AO staining of embryos exposed to IR. 
 
 
Ionizing radiation compromised zebrafish kidney function as determined by delayed excretion of 
a fluorescent dextran injected intracardially. 
Pre-treatment with EP but not CDDO-TFEA significantly reversed the effect of ionizing 
radiation on dextran clearance of irradiated embryos to near normal levels (Fig. 17), suggesting 
protection against radiation-induced renal toxicity.  
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Figure 17  Clearance of tetramethylrhodamine-labeled 10-kDa dextran was reduced after ionizing 
radiation (20 Gy) in relative to EP pretreated zebrafish exposed to ionizing radiation. In an unirradiated fish, 
dextran is rapidly cleared from the cardiac area. Effects of EP and CDDO-TFEA on radiation-induced 
kidney damage as determined by dextran clearance. A, Representative images of dextran retention in 
irradiated embryos and effects of EP and CDDO-TFEA on this phenomenon. B, Quantitative representation 
of dextran retention in embryos treated with either EP or CDDO-TFEA as indicated; results are expressed 
relative to vehicle-treated, non-irradiated controls. Asterices denote statistically significant differences 
between the experimental groups indicated by brackets. 
 
It is unknown whether this effect reflects differences in ROS scavenging capacity between the 
two compounds (Fig. 14) or is due to differences in pharmacokinetics or pharmacodynamics. In 
addition, radiation of zebrafish embryos is associated with a high incidence of the “curly-up” 
phenotype. Both CDDO-TFEA and EP reduced the incidence of curly-up significantly (Fig. 18). 
 
 
 
Figure 18 Pretreatment with either EP or CDDO-TFEA reduces the incidence of mid-line 
development. 
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Finally, we determined the effects of radiation on the developing gastrointestinal system. This 
was done in consideration of several prior reports suggesting that NF-κB activation protects the 
gastrointestinal tract of higher vertebrates against acute radiation damage [53] [54]. Radiation 
protection of the gastrointestinal system was determined in several ways.  
First, we assayed overall gastrointestinal function by scoring “long-term” survival of fish 
irradiated in the presence and absence of EP or CDDO-TFEA (up to 15 dpf). Fish larvae become 
dependent on external food sources at approximately 6 dpf when the contents of the yolk sac are 
depleted. Significant functional damage to the gastrointestinal system will thus lead to death by 
starvation within 10 days after conception [28]. Conversely, survival of zebrafish beyond two 
weeks indicates a functionally adequate gastrointestinal tract. Both EP and CDDO-TFEA 
prolonged survival of zebrafish larvae (Fig. 19) although this effect was statistically significant 
only in the case of CDDO-TFEA. 
 
 
Figure 19 “Long-term” survival of fish irradiated in the presence and absence of EP or CDDO-TFEA. 
Extended survival of irradiated zebrafish embryos pretreated with EP and CDDO-TFEA as determined at 15 
dpf.  
 
 
To address the combined effects of radiation and EP or CDDO-TFEA treatment on the 
developing gastrointestinal system further, we determined gastrointestinal lumen formation by 
use of the fluorescent reporter PED6 [29] that is metabolized and excreted through the 
gastrointestinal system. This analysis revealed severely impaired lumen formation of the 
gastrointestinal system induced by ionizing radiation (15 Gy) and partial restoration of lumen 
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formation and fluorescent dye excretion by treatment with either EP or CDDO-TFEA. These 
functional results were complemented by examining the histologic appearance of the 
gastrointestinal system 5 days after radiation exposure in the presence and absence of the NF-κB 
inhibitors under investigation (Fig. 20). 
 
Figure 20 Effects of EP and CDDO-TFEA on radiation-induced alterations of the gastrointestinal 
system.  A, Improved PLA2 activity and gastrointestinal lumen formation in irradiated zebrafish treated with 
either EP or CDDO-TFEA. Dequenched fluorescence reflects endogenous PLA2 activity and transport of 
cleavage products through the lumen of the developing gastrointestinal system. B, Quantitative evaluation of 
gastrointestinal lumen formation as determined by fluorescent dye content at 6 dpf. C, Representative 
histological sections of hindgut proximal to the cloaca at 6 dpf (5 days post radiation (12 Gy).  
The hindgut mucosal epithelium immediately proximal to the cloaca revealed distinct cellular 
changes associated with sublethal ionizing radiation exposure, including irregular shape and 
disorganization of the columnar absorbing cells with redistribution of nuclei away from the basal 
orientation.  In addition, decreased goblet cell numbers were observed. By contrast, EP and 
CDDO-TFEA pretreatment of irradiated embryos restored, in part, the columnar structure of 
absorbing cells and basal location of nuclei. 
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4.  DISCUSSION 
 
4.1.  DF-1 
The experiments with DF-1 illustrated that, as expected for an agent with antioxidant properties, 
DF-1 protected against and, at least to a limited extent, mitigated radiation-induced lethality in 
zebrafish embryos. 
The unmodified Buckminster fullerene C60 reportedly exerts toxic effect in vitro and in several 
in vivo systems including the aquatic largemouth bass [55]. This toxicity has been attributed, in 
part, to lipid peroxidation by C60.  In contrast to unmodified C60, DF-1 has been structurally 
altered to increase water solubility and, thereby potentially reduce C60-associated toxicity.   
The modified fullerene DF-1 provides radioprotection to several target tissues and organs and 
acts as an oxygen radical scavenger in this in vivo model system.  
 
4.2.  Manganese superoxide dismutase mimetics 
The degree of radioprotection provided by the SOD mimetics M40403 and MnTE-2-PyP5+ was 
comparable to that provided by Amifostine, but they proved to be effective at much lower 
concentrations, especially MnTE-2-PyP5+. Our finding is consistent with another report 
demonstrating the survival benefit of M40403 in mice exposed to lethal whole-body irradiation 
[56]. MnTE-2-PyP5+ was also reported to selectively protect normal cells but not tumor cells 
[57] against radiation-induced damage. 
 
 
4.3.  Direct inhibitors of NF-κB and proteasome inhibitors 
Our results show that 6 of 6 pharmacologic inhibitors with different chemical structures and 
mode of actions inhibited the canonical pathway of NF-κB activation (consisting of 
IKKβ/IκB/NF-κBp65) and provided protection against radiation-induced overall lethality and 
damage to multiple organ systems of the developing zebrafish. By contrast, 3 of 3 proteasome 
inhibitors did not afford radiation protection, but made zebrafish embryos more sensitive to the 
lethal effects of ionizing radiation. Taking into account that each of the pharmacologic agents 
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tested in this study is likely to affect targets other than NF-κB, it is remarkable that 
radioprotection co-segregated with interference with activation of the canonical pathway to NF-
κB. This observation suggests that NF-κB may be the relevant target for radiation protection by 
pharmacologic IKK/NF-κB inhibition.  
Currently, there is no consensus about the functional contribution of NF-κB activation to the 
radiation response [58]. Numerous reports of radiosensitization of tumor cells in vitro and in vivo 
by NF-κB inhibition are contrasted by relatively few such reports dealing with normal cells. The 
use of genetically engineered mouse models to monitor NF-κB dysfunction in normal tissues has 
been limited due to embryonic lethality observed in IKKβ [59] and NF-κBp65 [60] knockout 
animals. In cases where either conditional knockouts were made or transgenic mice were 
generated by forced expression of dominant negative regulators to modulate NF-κB activation, 
the interpretation of results is further complicated by compensatory adjustments of homeostasis 
[61]. This study sidesteps the problems inherent to using genetic models by examining the 
effects of pharmacologic agents applied at concentrations that reduce but do not abrogate NF-κB 
activity. Observation of overall effects of ionizing radiation on zebrafish survival as well as 
effects on specific target organs allowed us to monitor the effects of drug classes grouped 
according to target specificity and mechanisms of action. This approach had the advantage to 
minimize confounding effects due to unknown, off-target effects of any pharmacologic agent. As 
expected, ablating NF-κB activity by targeting IKKβ or NF κBp65 expression using antisense 
approaches led to a dramatically different outcome as these interventions were associated with 
embryonic lethality even in the absence of genotoxic stress (Fig. 12). This result is consistent 
with the view that inhibition of excess NF-κB activity following lethal irradiation is beneficial 
whereas blocking NF-κB expression and/or activation altogether, as in genetic 
knockout/knockdown models, is deleterious even in the absence of irradiation. This contention  
is also supported by our finding that EP and CDDO-TFEA at the nontoxic concentration used 
here disrupted TNF-α–induced NF-κB activation but not the basal NF-κB activity in HeLa cells 
in vitro (Fig. 8). Importantly, CDDO-TFEA and EP not only protected against but also mitigated 
the lethal effects of radiation. This result is of interest as it points to the importance of sustained 
NF-κB activation consistent with inflammatory responses rather than the burst of NF-κB activity 
observed immediately after radiation exposure.  
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Interestingly, radiation protection of zebrafish embryos by NF-κB inhibitors extended to the 
gastrointestinal system whereas previous work using genetically modified mice [53] and the 
TLR5 ligand flagellin [54] implicated NF-κB activation in radiation protection of gastrointestinal 
stem cells. The reason(s) for this difference are unclear at this point. However, the TLR5 ligand 
flagellin [54] exerts pleiotropic stimulatory effects on multiple signaling pathways that include 
NF-κB but also p38, Erk/mitogen-activated protein kinase, and potentially, signal transducers 
and activators of transcription [62]. It has not yet been reported which of these effects alone or in 
combination can result in radioprotection provided by flagellin [54].  
In addition, the NF-κB inhibitory effects of both EP and CDDO-TFEA are completely reversible, 
whereas genetic ablation is not, and this condition could affect the outcomes of NF-κB activation 
in reference to gastrointestinal function. Our findings are further consistent with the view that 
excessive NF-κB activation, as observed in the context of chronic inflammation, is potentially 
deleterious to the gastrointestinal system [63] and, thus, down-modulating NF-κB activity but not 
abolishing it altogether can be beneficial in certain settings [64]. Although the details of these 
diverse outcomes in different model systems remain to be sorted out, these results clearly show 
that reducing NF-κB activity with a variety of compounds with different mechanisms of action 
diminishes radiation-induced damage to several organ systems in the developing zebrafish 
embryos.  
In conclusion, the most salient finding of this study with NF-κB inhibitors is that direct inhibitors 
of NF-κB activity provided effective protection and mitigation against overall lethality and 
specific organ damage caused by ionizing radiation in zebrafish embryos. Direct NF-κB 
inhibitors also exert antineoplastic effects in select model systems as shown extensively for 
CDDO-TFEA and derivatives thereof [65-71]. These findings are consistent with a favorable 
therapeutic window for NF-κB inhibitors when used in combination with radiation and, 
potentially, chemotherapeutic drugs.  
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SUMMARY 
There is a great interest in developing radioprotectors to spare normal tissue during chemo- 
and/or radiotherapy or nuclear accidents.   
We used a relatively novel vertebrate organism, the zebrafish, as our experimental model system. 
This model has several advantages over conventional animal models: high fecundity, easy 
upkeep, large sample sizes, and high similarity to humans - the entire genome is sequenced. 
To achieve protection against ionizing radiation, we used different classes of drugs with distinct 
mechanisms of action. 
The radical oxygen scavenger DF-1 was tested first, which is a nanoparticle with a fullerene 
structure. Amifostine (the only radioprotector in clinical use) was used as a positive control. The 
chemically modified C60 compound proved effective affording protection of zebrafish embryos 
against a single dose of 20 Gy (which was previously defined as LD50) in all aspects of our 
study: morphology, overall survival, apoptosis as well as specific organ readouts including the 
kidney. 
We used zebrafish embryos to assess the capacity of two different classes of pharmacologic 
agents known to target NF-κB  to modify radiation toxicity in the vertebrate organism. These 
were direct inhibitors of NF-κB activity; that is, ethyl pyruvate and the synthetic triterpenoid 
CDDO-TFEA, and proteasome inhibitors, including PS-341, MG132 and lactacystin.  
The proteasome inhibitors either did not significantly affect radiation sensitivity of zebrafish 
embryos (MG132, lactacystin) or rendered zebrafish embryos more sensitive to the lethal effects 
of ionizing radiation (PS-341). Radiosensitization by PS-341 was reduced in fish with impaired 
p53 expression or function but not associated with enhanced expression of select p53 target 
genes. In contrast, the direct NF-κB inhibitors EP and CDDO-TFEA significantly improved 
overall survival of lethally irradiated zebrafish embryos. In addition, direct NF-κB inhibition 
reduced radiation-induced apoptosis in the central nervous system, abrogated aberrations in body 
axis development, restored metabolization and secretion of a reporter lipid through the 
gastrointestinal system, and improved renal clearance compromised by radiation. Unlike 
amifostine and DF-1, EP and CDDO-TFEA not only protected against but also mitigated 
radiation toxicity when administered 1 to 2 hours after ionizing radiation. Finally, four additional 
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IκB kinase inhibitors with distinct mechanisms of action similarly improved overall survival of 
lethally irradiated zebrafish embryos. In conclusion, inhibitors of canonical pathways to NF-κB 
activation may be useful in alleviating radiation toxicity in patients. 
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NEW FINDINGS RELATED TO THE THESIS 
 
1. Effects of the fullerene DF-1  
1.1. Effects on overall survival 
We demonstrated radioprotection by the fullerene DF-1 in our in vivo zebrafish model. 
DF-1 administered prior to irradiation afforded a significant survival advantage to zebrafish 
embryos exposed to either 20 Gy or 40 Gy.  
DF-1 was found to significantly enhance survival when given concurrently or up to 15 minutes 
after irradiation. 
1.2. Effects on organ-specific, radiation-induced damage 
DF-1 alleviated radiation-induced defects in the midline development of zebrafish embryos. It 
attenuated radiation-induced renal function defects.  
  
2. Effects of the proteasome inhibitor PS-341 (Bortezomib/VELCADE) 
PS-341 (1 μmol/L) markedly sensitized zebrafish embryos to the lethal effects of ionizing 
radiation when administered 1 hour prior to radiation.  
 
3. Effects of the NF-κBp65 inhibitor ethyl pyruvate 
We observed that EP not only protected against but also mitigated lethality associated with 
whole-body irradiation of zebrafish embryos. EP administered up to 2 hours after radiation 
significantly reduced ionizing radiation-associated lethality. EP was also found to be an effective 
ROS scavenger in irradiated zebrafish embryos.  
 
4. Effects of the IKK inhibitor CDDO-TFEA  
CDDO-TFEA protected against and mitigated overall lethal effects of radiation in zebrafish 
embryos in a manner similar to ethyl pyruvate. However, CDDO-TFEA, at least at the 
concentration (1 μM) applied in our experimental model, did not demonstrate ROS scavenging 
properties.  
 
5. Organ-specific radiation protection by CDDO-TFEA and EP 
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Both of them markedly reduced radiation-induced apoptosis as determined by acridine orange 
staining.  
Treatment with EP but not CDDO-TFEA significantly reversed the effect of ionizing radiation 
on dextran clearance of irradiated zebrafish embryos to near normal levels, suggesting protection 
against ionizing radiation-induced kidney damage. Both reduced the incidence of curly-up 
phenotype. We assayed overall gastrointestinal function by evaluating long-term survival (up to 
15 days) of zebrafish embryos irradiated in the presence and absence of either CDDO-TFEA or 
EP. Both compounds increased extended survival of zebrafish larvae. We also determined 
gastrointestinal lumen formation by use of the fluorescent reporter PED6. Pretreatment with EP 
or CDDO-TFEA restored, in part, the gastrointestinal lining of zebrafish embryos exposed to 
sublethal ionizing radiation exposure (12 Gy). 
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ÖSSZEFOGLALÁS 
Bevezetés: Az ionizáló sugárzás hatásait módosító anyagok az érdeklődés középpontjában 
állnak; jelentőségük meghatározó mind a kemo -és/vagy sugárterápia során, mind egy esetleges 
nukleáris baleset esetén. Egy kӧzelmúltban végzett vizsgálatunkban glioblastomával 
diagnosztizált betegekben alkalmazott onkoterápián belül terápiás modalitások komplex 
alkalmazásait hasonlítottuk össze. A temozolomid alkilálószer sugárkezeléssel szimultán 
alkalmazása a tumorsejtek radioszenzitizálása révén növeli a kezelés hatékonyságát. Ugyanakkor 
létfontosságú az ép szövetek megkímélése az ionizáló sugárzással szemben; az ép szöveti 
sugártolerancia emelésének kiemelt szerepe van a terápiás index javítása céljából. 
Tanulmányunkban döntően in vivo kísérleteink során a zebradániót (Danio rerio), illetve annak 
embrióit, használtuk kísérleti modellünkhöz. E modell fő előnyei más állatmodellekhez 
viszonyítva a következők: nagy mintaszám, az embriók transzparenciája, és nagy hasonlóság az 
emberi genomhoz.  A sugárhatást módosító anyagok közül klinikailag potenciálisan 
alkalmazhatók azon anyagok, mely szabad oxigéngyök fogó tulajdonságuk révén érik el a 
sugárvédelmet, illetve amelyek különböző molekuláris útvonalakon keresztül vezetnek 
sugárvédelemhez vagy sugárérzékenyítéshez. Általánosságban szignifikáns sugárvédelemre kis 
dózisú ionizáló sugárzás esetén számíthatunk, és a legtöbb sugárvédő anyag csak profilaktikusan 
alkalmazva képes radioprotektív hatást elérni.   
 
Célkitűzés és kérdésfelvetés: Az ionizáló sugárzás hatásait módosító anyagok tesztelése volt a 
célunk. Az ionizáló sugárzás hatásainak módosítására különböző gyógyszercsoportba tartozó, 
más-más hatásmechanizmusú anyagokat teszteltünk. 
Kísérleti zebradánió modellünkben azt vizsgáltuk, hogy a kutatásba bevont anyagok képesek-e a 
sugárzás káros hatásainak csökkentésére, a normál szöveti sugártolerancia javítására. Ha igen, 
akkor milyen mértékben és a sugárexpozíciót követően mennyi ideig képesek arra? Arra is 
kerestük a választ, hogy a teljes túlélés javításán túl milyen szerv-specifikus védelem érhető el a 
sugárzás károsító hatásaival szemben. 
 
Anyag és módszer: A kísérletes zebradánió modellben az ionizáló sugárzás hatásait vizsgáltuk 
ép, de fejlődésben lévő szövetekben teljestest-besugárzást követően. 
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Anyagok: Elsőként egy fullerén szerkezetű nanopartikulum, a DF-1, lehetséges radioprotektív 
tulajdonságait értékeltük a túlélést, valamint a szerv-specifikus védelmet tekintve. Preklinikai 
kísérleteink során szuperoxid-dizmutáz mimetikumok két tagját is vizsgáltuk. E két csoport 
potens szabadgyök-fogóként is ismert. A tanulmány másik részében olyan szereket használtunk, 
amelyekről ismert, hogy az NF-kappaB útvonalra is van hatásuk; ezek lehetséges sugárvédő 
vagy sugárérzékenyítő tulajdonságait teszteljük. Pozitív kontrollként – a humán felhasználásra 
már jóváhagyott sugárvédőt – az Amifostine-t használjuk. 
Besugárzás: Életképes, egészséges zebradánió embriókat 20 Gy fotonnal végzett teljestest-
besugárzásnak tettünk ki 24 órával a megtermékenyítést követően. A 20 Gy korábban LD50-ként 
volt definiálva, ezért választottuk ezt a dózist. A tesztelni kívánt anyagokat vagy a 
sugárexpozíció előtt vagy az után adtuk a halembriók médiumához.  
Teljes túlélés és szerv-specifikus vizsgálatok: Az embriókat 7 napon keresztül követtük. 
Megfigyeltük a morfológiai elváltozásokat, valamint detektáltuk a teljes túlélést. Az apoptózis 
értékelésére akridin-narancs fluoreszcens assay-t használtunk. A gasztrointesztinális védelem 
megítéléséhez funkcionális és hosszú távú vizsgálatot alkalmaztunk, hisztológiai metszetekett 
készítettünk. A vesefunkciót egy a dextrán molekula exkrécióján alapuló vizsgálattal értékeltük. 
Bizonyos anyagok esetén NF-κB  reporter assay-t és reverz transzkriptáz PCR-t is végeztünk, 
valamint használtunk antiszensz morfolinot is bizonyos kísérletekhez.   
 
Eredmények: Mind 20, mind 40 Gy besugárzás esetén a DF-1 által nyújtott védelem hasonló 
volt az Amifostine általi radioprotekcióhoz. A legnagyobb túlélési előnyt, akkor figyeltük meg 
modellünkben, amikor a DF-1-et 3 órával a besugárzás előtt adagoltuk. Szintén vizsgáltuk, hogy 
a DF-1 tudja-e csökkenteni  az ionizáló sugárzás káros hatásait, amikor a besugárzás után 
adagoltuk. Azt tapasztaltuk, hogy a DF-1 csak a sugárzást követő 15 percen belül adva volt 
képes javítani a túlélést.  A DF-1 csökkentette a sugárzás indukálta gerincdefektust, javította a 
besugárzást kӧvetően észlelhető csökkent vesefunkciót. A reaktív oxigén származékok mérése 
azt mutatta, hogy a szabadgyökök szintje jelentősen lecsökkent a DF-1-gyel előkezelt 
embriókban, míg az irradiált kontrollban magas maradt.  
Mindkét szuperoxid diszmutáz mimetikum szignifikánsan növelte a teljes túlélést a kontrollhoz 
képest. 
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A direkt NF-κB gátlók és a proteaszóma inhibitorok esetében megfigyeltük, hogy az NF-κB  
inhibitor etil-piruvát (EP) és CDDO-TFEA (szintetikus triterpenoid származék) védelmet 
biztosítottak az ionizáló sugárzás káros hatásai ellen, akkor is, ha a sugárexpozíció előtt vagy 
után (maximum 2 órával) adtuk ezen anyagok valamelyikét. Ez a sugárvédelem megmutatkozott 
több szerv tekintetében is, beleértve a gasztrointesztinális rendszert is. Ezzel szemben a 
proteaszóma inhibitor PS-341 (Velcade), melyet gyakran használnak az NF-κB  aktivitás 
gátlására mind in vitro, mind a humángyógyászatban, nem protektált, hanem fokozta a 
sugárzással összefüggő toxicitást zebradánió modellünkben.  
Diszkusszió: A DF-1-ről már ismert volt, hogy erős gyökfogó képességgel rendelkezik in vitro. 
Potens antioxidánskent sugárvédelmet nyújtott mind a teljes túlélés, mind pedig a szerv-
specifikus védelem tekintetében. A DF-1-gyel szerzett eredményeket összefoglalva, ezek a 
kísérletek is bizonyították, mint ahogy az várható volt egy antioxidánstól, hogy ez a módosított 
fullerén származék a sugárzást követően adagolva csak limitált ideig volt képes csökkenteni az 
ionizáló sugárzás káros hatásait.  
A hat farmakológiai inhibitor (EP, CDDO-TFEA, és négy, kis molekulájú IKK gátló), mely a 
kanonikus NF-κB útvonalat gátolja, képes volt védelmet nyújtani az ionizáló sugárzás káros 
hatásai ellen. Ezzel szemben, az általunk vizsgált három proteaszóma inhibitor sugárvédelmet 
egyáltalán nem adott, hanem inkább érzékenyítette a zebradánió embriókat a sugárzással 
szemben.  
A tumorsejtek NF-κB gátláson keresztüli sugárérzékenyítéséről nagyszámú tanulmány érhető el, 
míg az ionizáló sugárzásnak kitett normál szövetek és az NF-κB gátlás kapcsolatáról viszonylag 
kevesebb cikk áll rendelkezésre. A genetikailag módosított egér modellek alkalmazása limitált az 
NF-κB diszfunkció ép szövetekben való tanulmányozására, mivel  az IKKβ és az NF-κBp65 
knockout állatok nem életképesek. Tanulmányunk megkerüli a fenti problémát, mert 
farmakológiai szereket használtunk olyan koncentrációban, amely az NF-κB aktivitást csökkenti, 
de nem gátolja teljesen. Ez a megközelítés lehetővé tette számunkra, hogy megfigyeljük ezen, 
különböző target specificitású és hatásmechanizmusú anyagok hatásait in vivo, valamint 
minimalizálta a farmakológiai szer ismeretlen, off-target hatása miatti zavaró tényezőket. Ahogy 
az várható volt, az antiszensz technikával az IKKβ és NF-κB p65 expresszió kiütésén keresztüli 
NF-κB gátlás embrionális letalitáshoz vezetett még genotoxikus stressz, esetünkben ionizáló 
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sugárzásnak való kitettség, nélkül is. Ez az eredmény konzisztens azzal a nézettel, hogy a 
besugárzást követő excesszív NF-κB aktivitás gátlása előnyös, míg az NF-κB expresszió és/vagy 
aktiváció teljes gátlása ártalmas, letális. Ennek megerősítését alátámasztja az a megfigyelésünk, 
hogy mind az EP, mind pedig a CDDO-TFEA nem toxikus koncentrációban csökkentette a TNF-
α indukálta NF-κB aktivitást, de nem érintette a bazális NF-κB aktivitást HeLa sejtekben. 
Kiemelendő, hogy az EP és a CDDO-TFEA nem csak a normál szöveti sugártoleranciát növelte, 
hanem a sugárexpozíciót követően 2 órán belül adva is javította a túlélést. Ez az eredmény 
inkább a gyulladásos válaszokra jellemző hosszantartó NF-κB aktiváció jelentőségére mutat rá, 
mint a közvetlenül a sugárexpozíció utáni hirtelen NF-κB aktivitás  növekedésére.  
Konklúzió: A tanulmány legfontosabb eredménye, hogy a direkt NF-κB gátlók hatékony 
sugárvédelmet nyújtottak mind a teljes túlélés, mind a szerv-specifikus védelem tekintetében az 
ionizáló sugárzás káros hatásai ellen. A direkt NF-κB inhibitorok antineoplasztikus hatást is 
kifejtenek, ahogyan azt más csoportok mutatták a szintetikus triterpenoid származékok esetében. 
Az NF-κB inhibitorok besugárzással és, potenciálisan, kemoterápiával való kombinálása 
hozzájárulhat a terápiás index javításához. 
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